Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
COVID-19 Booster Study Shows Efficacy: Daiichi Sankyo
Daiichi Sankyo said on May 26 that its investigational mRNA vaccine against COVID-19 (DS-5670) demonstrated efficacy in a domestic booster dose trial. The results of this first dose-finding part in the Japan PI/II/III clinical study showed that the booster effect…
To read the full story
Related Article
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Daiichi Sankyo’s COVID Jab Hits Mark in Japan Booster Trial, Filing Set for January
November 16, 2022
- Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab
September 2, 2022
- Daiichi Sankyo Initiates COVID-19 Booster Study in Japan
February 1, 2022
- Daiichi Sankyo Begins PII for COVID-19 mRNA Vaccine, Eyes 2022 Rollout
November 18, 2021
- Daiichi Sankyo Eyes Booster Dose Trial Launch in January
October 22, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
BUSINESS
- Datroway Accepted for US Review for 1st-Line TNBC: Daiichi Sankyo
February 4, 2026
- Veozah Hits Primary Goal in Japan PIII Study: Astellas
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Nippon Kayaku’s Avastin Biosimilar Share Hits 58%
February 3, 2026
- Japan’s 1st OTC Morning-After Pill Now Available
February 3, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…